Terlax (Tizanidine)

ٹیبلیٹ

۲، ۳ ملی گرام

COMPOSITION:

Terlax 2mg Tablet

Each tablet contains: Tizanidine (as HCI)…. .2mg

Terlax 4mg Tablet

Each tablet contains:

Tizanidine (as HCI)………….4mg

Tizanidine is a centrally acting skeletal muscle relaxant. Its principal site of action is the spinal cord, where the evidence suggests that, by stimulating presynaptic a,-receptors, it inhibits the release of excitatory aminoacids that stimulate trauma. N-methyl-D aspartate (NMDA) receptors.

Polysynaptic signal transmission at spinal interneuron level, which is responsible for (e.g.) excessive muscle tone, is thus inhibited and muscle tone is reduced. Notwithstanding its muscle-relaxant properties, tizanidine likewise applies a moderate focal pain relieving impact. Tizanidine is viable in both intense agonizing muscle fits and persistent spasticity of spinal and cerebral beginning. It diminishes protection from detached developments, lightens fits and clonus, and may work on intentional strength.

PHARMACOKINETIC PROPERTIES Absorption and bioavailability:

Tizanidine is quickly and totally ingested, arriving at top plasma fixation around 1 hour in the wake of dosing. Mean absolute bioavailability is about 34% due to extensive

first-pass metabolism.

Distribution:

Mean steady-state volume of distribution following I.V. administration is 2.6 L/kg. Plasma protein binding is 30%, Tizanidine has linear pharmacokinetics over the dose range 4 to 20mg. . The low intraindividual variety in pharmacokinetic boundaries (Cmax and AUC) empowers solid forecast of plasma levels following oral organization.

Biotransformation:

The medication has been demonstrated to be quickly and widely utilized by the liver. The metabolites give off an impression of being dormant.

Elimination:

Tizanidine is wiped out from the foundational flow with a mean terminal half-existence of 2 to 4 hours. Discharge is principally by means of the kidneys (roughly 70% of portion) as metabolites, with unaltered medication representing just around 2.7% of urinary recuperation.

INDICATIONS:

Painful muscle spasms Associated with static and functional disorders of the spine (cervical and lumbar syndromes). . Muscular spasms associated with accidental

Multiple sclerosis, chronic myelopathy. degenerative spinal cord diseases. cerebrovascular accidents, and cerebral palsy.

DOSAGE & ADMINISTRATION:

Painful muscle spasms

Terlax 2 to 4 mg three times daily. In serious cases an additional portion of 2 or 4 mg might be taken around evening time.

The dosage should be adjusted to the needs of the individual patients.

The initial daily dose should not exceed 6mg given in 3 divided doses. The daily dose of 36mg should not be exceeded.

USE IN CHILDREN:

Experience in children is limited and the use of Tizanidine in this patient population is not recommended.

CONTRAINDICATIONS:

Known hypersensitivity to Tizanidine or any component of the formulation.

SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE:

Special warnings

Careful administration in patients with severe hepatic dysfunction.

Tizanidine has no teratogenic impacts in rodents and hares.

UNDESIRABLE EFFECTS:

Undesirable effects are usually mild and transient, includes, somnolence, drowsiness, fatigue, dizziness, dry mouth, slight reduction in blood pressure, nausea, gastrointestinal disturbances, transient increase in serum transaminases, hypotension, bradycardia, muscle weakness, insomnia, sleep disorders, hallucination, acute hepatitis.

OVERDOSAGE:

Symptoms

Nausea, vomiting, hypotension, dizziness, somnolence, miosis restlessness, respiratory distress, coma.

Treatment:

Tizanidine, Further treatment should be symptomatic.

PRESENTATION:

Terlax 2mg Tablet is available in a pack of 10’s Terlax 4mg Tablet is available in a pack of 10’s

STORAGE CONDITIONS:

Store below 30°C. Protect from light & moisture.

Use only on medical advice. Keep out of reach of children. For oral use only.

دوا کو روشنی اور کسی سے محفوظ ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر رکھیں۔ لم

دوا ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔ دوا بچوں کی پہنچ سے دور رکھیں ۔ صرف کھانے کے لیے استعمال کریں۔

Manufactured by

Barrett Hodgson

Pakistan (Pvt) Ltd

F/423, SITE, Karachi-75700

TERLTDC/004
Hivatement (Mometasone Furoate U.S.P)

Terlax (Tizanidine)